A Clinical Study to Assess the Efficacy of Cannabigerol in Patients with Active Rheumatoid Arthritis.

A Clinical Study to Assess the Efficacy of Cannabigerol in Patients with Active Rheumatoid Arthritis.

This is a single-group exploratory longitudinal prospective study lasting 8 weeks. The study aims to measure the efficacy of purified cannabigerol (CBG) in patients with active rheumatoid arthritis using laboratory and self-reported outcome measures.

Inclusion Criteria:

• Male or female, over 25 years of age
• Positive anti-CCP blood test
• Active RA-related inflammation with at least 2 swollen joints
• University graduate
• Generally healthy with no uncontrolled chronic disease
• Able to read, understand, and sign informed consent
• Resides in the USA
• Willing to comply with study requirements and avoid other cannabis products during the study period

Exclusion Criteria:

• Pre-existing chronic conditions preventing adherence
• Severe allergic reactions requiring an Epi-pen
• Use of opiates in the last 4 weeks or cannabis in the last 8 weeks
• Pregnant or breastfeeding women
• Recent invasive medical procedure or surgery
• Active malignancy or ongoing oncology treatment
• Use of cytochrome P450 or 3A4 inhibitors
• History of substance abuse